Categories
- Cancer
- Cardiovascular
- Diabetes
- Eye, Ear, Nose & Throat
- Gastro-intestinal
- Genito-urinary
- Infections & Immunology
- Men's Health
- Mental Health & CNS
- Musculoskeletal
- Nutrition
- Paediatrics
- Respiratory
- Skin
- Women's Health
Archives
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- April 2007
- March 2007
- February 2007
- January 2007
- December 2006
Tagcloud
abortion, accupuncture, ACE inhibitors, acne, ADHD, alcohol, allergies, Alzheimer's, anaemia, anaethesia, anorexia, antibiotics, antidepressants, antihistamine, anxiety, appetite control, arthritis, ASCOT, aspirin, asthma, atherosclerosis, autism, autoantibodies, back pain, beta carotene, beta-blockers, bipolar disorder, birth, bleeding, blindness, blood pressure, body dysmorphic disorder, body mass, breast cancer, breast feeding, bronchitis, Caesarean section, calcium, cancer, carcinogens, carcinoma, cardiac syncope, cardiolgy, cataracts, cervical cancer, chemotherapy, child psychiatry, children, cholesterol, clinical trial, clopidogrel, Clostridium difficile, cognitive behavioural therapy, colectomy, colic, colorectal cancer, complementary and alternative therapies, contraception, COPD, coronary care, coronary stents, Crohn's, cystic fibrosis, defibrillator, dementia, depression, dermatology, diabetes management, diet, disability, DNA, Down's syndrome, eating disorders, echinacea, ECT, eczema, elderly people, endoscopy, epilepsy, erectile dysfunction, euthanasia, exercise, fat, fertility, fitness, flu pandemic, fluoxetine, folic acid, food labelling, fracture, fragile X syndrome, general surgery, genetics, gerontology, GIK infusion therapy, GORD, gout, haemodialysis, hearing, heart attack, heart disease, heart failure, heart health, hepatitis, HIV, hospital care, HPV, HRT, hyperglycaemia, hypertension, hypoglycaemia, IBD, ICU, incontinence, infant, infant mortality, infection, inflammatory bowel disease, influenza, invasive candidiasis, IQ, Irish Heart Foundation, irritable bowel syndrome, keyhole surgery, kidney disease, laser, learning difficulties, leukaemia, liver disease, lumbar disk herniation, lung cancer, lung disease, lymph nodes, macular degeneration, macular oedema, magnetic resonance imaging (MRI), malaria, malnutrition, Marfan syndrome, media, medical ethics, medical research, medication, meningitis, mental illness, metabolic syndrome, migraine, miscarriage, mortality rate, MRSA, multiple sclerosis (MS), NCHDs, nephrology, neurology, OAB, obesity, obstetrics, occupational health, ocular medicine, omega-3, opthalmology, oral cancer, organ transplantation, orthopaedics, osteoporosis, otolaryngology, ovarian cancer, paediatrics, pain management, pancreatic cancer, panic, Parkinson’s disease, patient safety, patient-physician communication, personality disorders, physiotherapy, plastic surgery, polio, practice, pre-eclampsia, pregnancy, preventative health care, probiotics, prostate cancer, psoriasis, psychiatric admission, psychiatry, psychotherapy, PTSD, public health, quality of life, radiology, radiotherapy, rectal cancer, reproductive health, research, resuscitation, rheumatoid arthritis, rheumatology, rhinitis, salt, SARS, schizophrenia, screening, seizures, self harm, sexual abuse, sexual health, sexually transmitted infections, SGA, sinusitis, skin cancer, sleep disorders, smoking, smoking ban, spinal injury, sports medicine, statins, stress, stroke, substance abuse, suicide, supplement, surgery, syncope, technology, teenagers, testosterone, thoracic surgery, thrombosis, thyroid cancer, tonsillectomy, tonsillitis, Tourette's syndrome, toxicology, travel medicine, tuberculosis, tumour angiogenesis, type 1 diabetes, type 2 diabetes, ulcer, ulcerative colitis, urinary incontinence, vaccine, vitamins, weight, WHO, women's health, World Health Assembly
«Previous article | Next article»
Progesterone-only pills appeal to women for various reasons
Clinical Update - Contraception: Previous progesterone-only pills did not regularly prevent ovulation, and there was a higher failure rate with them, according to Dr Caitriona Henchion, Medical Director of the Irish Family Planning Association.
The previous pills acted on local mechanisms. Cervical mucus was thickened. This made it difficult for sperm to penetrate. The lining of the womb was changed, hindering implantation. Those changes, however, are temporary. The ovaries could be producing eggs, and if a three-hour window for taking the pill is missed, a pregnancy might occur.
Pills that do not contain oestrogen are considered more suitable for women over 35 years with migraine – and particularly for those women who have focal migraine with visual changes. It may be wise for women who have had previous clotting problems to avoid taking oestrogen.
Oestrogen can slightly increase the risk of breast cancer but the absolute risk is small.
Progesterone-only pills appeal to a number of women for these reasons. A number of new progesterone-only treatments have become available recently.
With the older Noriday minipill, a woman could be late by up to three hours in taking a pill. If women were more than three hours late, that would be considered a ‘missed pill’, meaning a woman would have to wait seven days before she is protected and covered by contraception again.
Cerezette is a new product to the market that prevents ovulation as much as the combined pills (at a rate of around 98 per cent). This action makes a 12-hour window for taking this pill possible.
Cerezette’s 12-hour window is the same as that of regular combined oestrogen/progesterone pills.
The progesterone-only pills are all 28-day packs, and this improves compliance. There have been two new combined pills recently. Both have 28-day formulations.
Yaz is a low dose treatment, which has 24 active pills and four daily placebo pills. The treatment also has a shortened ‘break’, which reduces the rate of failures as well.
Side effects may also be reduced. With previous con-traceptives, some women found that towards the end of their pill-free week, they got headaches or pre-menstrual symptoms. “The shorter break with Yaz means this is much less likely to happen,” Dr Henchion said.
Another new treatment, Qlaira, offers good cycle control and reliable contraceptive effects. This treatment contains a natural oestrogen. There are two placebo pills at the end, so a break between packs is not needed.
The oestrogen in all of the pills up to now has been ethinyl estradiol (the closest it had been possible to get to natural estradiol).
In September, Qlaira was licensed. In Qlaira, the ethinyl part has been removed, so the estradiol should be the same as the estradiol valerate in the woman’s own system. Theoretically, this should be better than a synthetic hormone.
Posted in Genito-urinary on 20 November 2009
Tags:
More articles from IMT Clinical Times
